Ira Duarte's most recent trade in Heron Therapeutics Inc was a trade of 11,694 Restricted Stock Units done . Disclosure was reported to the exchange on April 30, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Heron Therapeutics Inc | Duarte Ira | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 11,694 | 175,416 | - | - | Restricted Stock Units | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 11,694 | 136,149 (0%) | 0% | - | Common Stock | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2025 | 3,875 | 42,617 | - | - | Restricted Stock Units | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2025 | 3,875 | 124,455 (0%) | 0% | - | Common Stock | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 374,220 | 374,220 | - | - | Employee Stock Option (Right to Buy) | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 187,110 | 187,110 | - | - | Restricted Stock Units | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 3,874 | 120,580 (0%) | 0% | - | Common Stock | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 3,874 | 46,492 | - | - | Restricted Stock Units | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 3,874 | 50,366 | - | - | Restricted Stock Units | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 3,874 | 108,001 (0%) | 0% | - | Common Stock | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 3,875 | 104,127 (0%) | 0% | - | Common Stock | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 3,875 | 54,240 | - | - | Restricted Stock Units | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,500 | 100,252 (0%) | 0% | - | Common Stock | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,500 | 37,500 | - | - | Restricted Stock Units | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 3,874 | 88,874 (0%) | 0% | - | Common Stock | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 3,874 | 58,115 | - | - | Restricted Stock Units | |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.64 per share. | 19 Apr 2024 | 1,122 | 87,752 (0%) | 0% | 2.6 | 2,962 | Common Stock |
Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 371,935 | 371,935 | - | - | Employee Stock Option (Right to Buy) | |
Heron Therapeutics Inc | Duarte Ira | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 61,989 | 61,989 | - | - | Restricted Stock Units |